MLAB PE Ratio & Valuation,Is MLAB Overvalued

MLAB Relative Valuation

MLAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MLAB is overvalued; if below, it's undervalued.

Historical Valuation

Mesa Laboratories Inc (MLAB) is now in the Overvalued zone, suggesting that its current forward PE ratio of 59.59 is considered Overvalued compared with the five-year average of 32.35. The fair price of Mesa Laboratories Inc (MLAB) is between 27.31 to 62.59 according to relative valuation methord. Compared to the current price of 77.77 USD , Mesa Laboratories Inc is Overvalued By 24.26%.

Relative Value

Fair Zone

27.31-62.59

Current Price：77.77

24.26%

Overvalued

59.59

9.29

EV/EBITDA

Mesa Laboratories Inc. (MLAB) has a current EV/EBITDA of 9.29. The 5-year average EV/EBITDA is 19.48. The thresholds are as follows: Strongly Undervalued below 5.41, Undervalued between 5.41 and 12.45, Fairly Valued between 26.52 and 12.45, Overvalued between 26.52 and 33.55, and Strongly Overvalued above 33.55. The current Forward EV/EBITDA of 9.29 falls within the Undervalued range.

9.84

EV/EBIT

Mesa Laboratories Inc. (MLAB) has a current EV/EBIT of 9.84. The 5-year average EV/EBIT is 21.63. The thresholds are as follows: Strongly Undervalued below 0.34, Undervalued between 0.34 and 10.98, Fairly Valued between 32.27 and 10.98, Overvalued between 32.27 and 42.91, and Strongly Overvalued above 42.91. The current Forward EV/EBIT of 9.84 falls within the Undervalued range.

1.69

Mesa Laboratories Inc. (MLAB) has a current PS of 1.69. The 5-year average PS is 4.34. The thresholds are as follows: Strongly Undervalued below -0.59, Undervalued between -0.59 and 1.87, Fairly Valued between 6.81 and 1.87, Overvalued between 6.81 and 9.27, and Strongly Overvalued above 9.27. The current Forward PS of 1.69 falls within the Undervalued range.

11.04

P/OCF

Mesa Laboratories Inc. (MLAB) has a current P/OCF of 11.04. The 5-year average P/OCF is 21.17. The thresholds are as follows: Strongly Undervalued below -2.01, Undervalued between -2.01 and 9.58, Fairly Valued between 32.77 and 9.58, Overvalued between 32.77 and 44.36, and Strongly Overvalued above 44.36. The current Forward P/OCF of 11.04 falls within the Historic Trend Line -Fairly Valued range.

12.96

P/FCF

Mesa Laboratories Inc. (MLAB) has a current P/FCF of 12.96. The 5-year average P/FCF is 24.11. The thresholds are as follows: Strongly Undervalued below -2.63, Undervalued between -2.63 and 10.74, Fairly Valued between 37.48 and 10.74, Overvalued between 37.48 and 50.85, and Strongly Overvalued above 50.85. The current Forward P/FCF of 12.96 falls within the Historic Trend Line -Fairly Valued range.

Mesa Laboratories Inc (MLAB) has a current Price-to-Book (P/B) ratio of 2.40. Compared to its 3-year average P/B ratio of 2.86 , the current P/B ratio is approximately -16.11% higher. Relative to its 5-year average P/B ratio of 3.02, the current P/B ratio is about -20.43% higher. Mesa Laboratories Inc (MLAB) has a Forward Free Cash Flow (FCF) yield of approximately 8.67%. Compared to its 3-year average FCF yield of 6.19%, the current FCF yield is approximately 39.97% lower. Relative to its 5-year average FCF yield of 4.77% , the current FCF yield is about 81.79% lower.

2.40

P/B

Median3y

2.86

Median5y

3.02

8.67

FCF Yield

Median3y

6.19

Median5y

4.77

Competitors Valuation Multiple

The average P/S ratio for MLAB's competitors is 116.72, providing a benchmark for relative valuation. Mesa Laboratories Inc Corp (MLAB) exhibits a P/S ratio of 1.69, which is -98.55% above the industry average. Given its robust revenue growth of 5.02%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of MLAB decreased by 41.03% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 57.83M to 60.74M.

The secondary factor is the P/E Change, contributed -14.85%to the performance.

Overall, the performance of MLAB in the past 1 year is driven by Revenue Growth. Which is more sustainable.

5.02%

57.83M → 60.74M

Revenue Growth

-31.20%

5.93 → 4.08

Margin Expansion

-14.85%

-317.33 → -270.21

P/E Change

-41.03%

131.87 → 77.77

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Mesa Laboratories Inc (MLAB) currently overvalued or undervalued?

What is Mesa Laboratories Inc (MLAB) fair value?

MLAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Mesa Laboratories Inc (MLAB) is between 27.31 to 62.59 according to relative valuation methord.

How does MLAB's valuation metrics compare to the industry average?

What is the current P/B ratio for Mesa Laboratories Inc (MLAB) as of Dec 15 2025?

As of Dec 15 2025, Mesa Laboratories Inc (MLAB) has a P/B ratio of 2.40. This indicates that the market values MLAB at 2.40 times its book value.

What is the current FCF Yield for Mesa Laboratories Inc (MLAB) as of Dec 15 2025?

As of Dec 15 2025, Mesa Laboratories Inc (MLAB) has a FCF Yield of 8.67%. This means that for every dollar of Mesa Laboratories Inc’s market capitalization, the company generates 8.67 cents in free cash flow.

What is the current Forward P/E ratio for Mesa Laboratories Inc (MLAB) as of Dec 15 2025?

As of Dec 15 2025, Mesa Laboratories Inc (MLAB) has a Forward P/E ratio of 59.59. This means the market is willing to pay $59.59 for every dollar of Mesa Laboratories Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Mesa Laboratories Inc (MLAB) as of Dec 15 2025?

As of Dec 15 2025, Mesa Laboratories Inc (MLAB) has a Forward P/S ratio of 1.69. This means the market is valuing MLAB at $1.69 for every dollar of expected revenue over the next 12 months.

MLAB Valuation